Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. is a phase 3, randomised interventional study registered as NCT03869892 by Institut de Recherches Internationales Servier, with a registry enrolment figure of 856 participants, started 2019-03-21 and due to reach its primary completion in 2021-06-29. Interventions recorded: Trifluridine/tipiracil hydrochloride (S95005); Capecitabine; Bevacizumab experimental; Bevacizumab control. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Progression-free Survival (PFS). Colorectal eligibility wording from the registry: "Has definitive histologically confirmed adenocarcinoma of the colon or rectum (all other histological types are excluded)". Sites: Argentina, Australia, Austria, Brazil, Bulgaria, Czechia, Denmark, Estonia, France, Germany, Hungary, Ireland and 13 more countries. United Kingdom sites listed: 11. No results are recorded here; the registry entry is the source.